Phase I
Boehringer Ingelheim and OSE Immunotherapeutics signed a collaboration and license deal to jointly develop OSE-172 for myeloid cancers.
Vivaldi Biosciences announced that its chief scientific officer is delivering a presentation today at the World Vaccine Congress. A new nonclinical trial shows that deltaFLU protected against both distantly drifted and shifted influenza strains, as compared to leading licensed flu vaccines.
The $40 billion market for nonalcoholic steatohepatitis (NASH) is becoming a little more crowded. Less than one year after launching Terns Pharmaceuticals acquired exclusive licensing rights to three small molecule therapeutic NASH candidates from Eli Lilly.
Pfizer, based in New York City, and Allogene Therapeutics, based in South San Francisco, entered into an asset contribution deal, as well as a $300 million Series A round.
Synlogic, based in Cambridge, Massachusetts, announced it had dosed its first patient in its Phase Ib/IIa clinical trial of SYNB1020 for hyperammonemia.
Redx Pharma dosed its first patient for the Porcupine inhibitor RXC004 on February 6. The company indicates it has paused the trial after the first patient dosed had “clinically significant” adverse events.
Homology Medicines has raised $144 million in an initial public offering of stock.
Analysts look at what else AbbVie has in the pipeline after Rova-T Failure.
A common treatment used to break up the clots and prevent brain damage has become mired in controversy. The treatment, called tissue plasminogen activator (TPA), demonstrated in a clinical trial that the medicine could break up those blood clots and prevent brain damage.
Denali Therapeutics, located in South San Francisco, California, had a lot of news to share today.
PRESS RELEASES